Commercial
Advanced Search
Type
  
Name
  
MPPolicyNumber
  
MPDispTitle
  
Policy Category
  
Title
  
MPPolicyPageName
  
ID
  
MPTitle
  
MPPolicyNumberwithoutversion
  
MPattachmentdataPub
9218d81f-664c-4325-86e2-b7cdfee1f8d5.aspx
  
07.00.14h​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Low-LevelLaserTherapy07.00.14hMedicine (07)​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Low-Level Laser Therapy9218d81f-664c-4325-86e2-b7cdfee1f8d56600​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Low-Level Laser Therapy07.00.14
488dec00-d5ea-416c-86b2-e1e16d582e79.aspx
  
08.00.62qAbatacept(Orencia®)forInjectionforIntravenousUse08.00.62qPharmacy (08)Abatacept (Orencia®) for Injection for Intravenous Use488dec00-d5ea-416c-86b2-e1e16d582e796641Abatacept (Orencia®) for Injection for Intravenous Use08.00.62
{"6642": {"Id":6642,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":8937,"PolicyAttachmentPageName":"615490c4-cfdc-4742-85d2-cd9e840106ed"},}
982834a7-91a7-4cdf-a7a0-a9f78390e73f.aspx
  
12.00.01iAcupuncture12.00.01iMiscellaneous (12)Acupuncture982834a7-91a7-4cdf-a7a0-a9f78390e73f7134Acupuncture12.00.01
{"7135": {"Id":7135,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":9445,"PolicyAttachmentPageName":"9a719f8e-39e5-41eb-9221-17243a66e283"},}
ad65734f-8c9d-4c0a-b362-9b3677e62f35.aspx
  
12.04.04bAcuteCareFacilityInpatientTransfers12.04.04bMiscellaneous (12)Acute Care Facility Inpatient Transfersad65734f-8c9d-4c0a-b362-9b3677e62f356190Acute Care Facility Inpatient Transfers12.04.04
d5e67f8a-f5e2-4997-8424-41e3b326d8b7.aspx
  
08.02.21ADAMTS13,recombinant-krhn(Adzynma)08.02.21Pharmacy (08)ADAMTS13, recombinant-krhn (Adzynma)d5e67f8a-f5e2-4997-8424-41e3b326d8b76515ADAMTS13, recombinant-krhn (Adzynma)08.02.21
b2f741cb-d1fd-49a3-91e0-bf9f2d147f8d.aspx
  
08.01.11iAdo-TrastuzumabEmtansine(Kadcyla®)08.01.11iPharmacy (08)Ado-Trastuzumab Emtansine (Kadcyla®)b2f741cb-d1fd-49a3-91e0-bf9f2d147f8d6105Ado-Trastuzumab Emtansine (Kadcyla®)08.01.11
{"6106": {"Id":6106,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes and Narratives","MPPolicyAttachmentInternalSourceId":8429,"PolicyAttachmentPageName":"f3dcbb05-9707-4ad4-9b88-6be3d7172267"},}
6df88e0d-d8e3-4162-93fb-7747badd3e30.aspx
  
08.02.32aAfamitresgeneautoleucel(Tecelra®)08.02.32aPharmacy (08)Afamitresgene autoleucel (Tecelra®)6df88e0d-d8e3-4162-93fb-7747badd3e307264Afamitresgene autoleucel (Tecelra®)08.02.32
2e032683-3b7c-4677-a7c8-f74557ec2fab.aspx
  
08.00.69dAgalsidasebeta(Fabrazyme®)andpegunigalsidasealfa-iwxj(Elfabrio)08.00.69dPharmacy (08)Agalsidase beta (Fabrazyme®) and pegunigalsidase alfa-iwxj (Elfabrio) 2e032683-3b7c-4677-a7c8-f74557ec2fab6616Agalsidase beta (Fabrazyme®) and pegunigalsidase alfa-iwxj (Elfabrio) 08.00.69
245ffd2b-6443-450c-854f-d6716f6c1f0c.aspx
  
12.04.03cAirAmbulanceServices12.04.03cMiscellaneous (12)Air Ambulance Services245ffd2b-6443-450c-854f-d6716f6c1f0c6418Air Ambulance Services12.04.03
48642be3-8920-4056-9bc1-f3fa8eaafd73.aspx
  
08.01.22dAlemtuzumab(Lemtrada®)08.01.22dPharmacy (08)Alemtuzumab (Lemtrada®)48642be3-8920-4056-9bc1-f3fa8eaafd737247Alemtuzumab (Lemtrada®)08.01.22
acd08093-ff2e-4a25-bd88-d5bba1956861.aspx
  
08.00.72lAlglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®),Cipaglucosidasealfa-atga(Pombiliti™)08.00.72lPharmacy (08)Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ )acd08093-ff2e-4a25-bd88-d5bba19568616240Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ )08.00.72
f9143396-59dc-41c7-b0bd-3276abbd228c.aspx
  
07.00.21jAllergyImmunotherapy07.00.21jMedicine (07)Allergy Immunotherapyf9143396-59dc-41c7-b0bd-3276abbd228c6262Allergy Immunotherapy07.00.21
07a9501c-7555-435e-851a-cd30d2599ca7.aspx
  
08.01.88AllogeneicProcessedThymusTissue-agdc(Rethymic®)08.01.88Pharmacy (08)Allogeneic Processed Thymus Tissue-agdc (Rethymic®)07a9501c-7555-435e-851a-cd30d2599ca77206Allogeneic Processed Thymus Tissue-agdc (Rethymic®)08.01.88
441bf6fa-8d20-4f99-a633-1df6e903aadb.aspx
  
06.02.29gAlloMap™MolecularExpressionTestingforHeartTransplantRejection(IndependenceAdministrators)06.02.29gPathology and Laboratory (06)AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)441bf6fa-8d20-4f99-a633-1df6e903aadb7128AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)06.02.29
d32eec72-479b-43a6-bdf3-cfe24dfa12b2.aspx
  
08.00.91eAlpha1-AntitrypsinTherapy(e.g.,Prolastin-C®,AralastNP®,Glassia®,Zemaira®)08.00.91ePharmacy (08)Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)d32eec72-479b-43a6-bdf3-cfe24dfa12b26266Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)08.00.91
18221a36-d1f4-43de-82c2-6f98b949fee1.aspx
  
00.01.52xAlwaysBundledProcedureCodes00.01.52xAdministrative (00)Always Bundled Procedure Codes18221a36-d1f4-43de-82c2-6f98b949fee17046Always Bundled Procedure Codes00.01.52
{"7047": {"Id":7047,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":9400,"PolicyAttachmentPageName":"0b8420f1-12ed-4c99-ac20-ae9f3d7d4a5c"},"7048": {"Id":7048,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":9401,"PolicyAttachmentPageName":"39d00bff-ceb4-4b8f-9e1d-9b786d1def7e"},"7049": {"Id":7049,"MPAttachmentLetter":"A","Title":"Always Bundled Procedures (Indicator B)","MPPolicyAttachmentInternalSourceId":9402,"PolicyAttachmentPageName":"f53e865e-e70f-4458-9aac-5bdfc97aa952"},}
eeb386be-be45-43cb-b8dd-5eaca1df97ee.aspx
  
07.02.09jAmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)Devices07.02.09jMedicine (07)Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Deviceseeb386be-be45-43cb-b8dd-5eaca1df97ee6660Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices07.02.09
ba42d838-ddc7-45b0-b065-6b90274bde77.aspx
  
07.02.21qAmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)Monitoring07.02.21qMedicine (07)Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoringba42d838-ddc7-45b0-b065-6b90274bde777005Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring07.02.21
22e3725e-1aab-4c4e-a86b-bd4cb90f60b2.aspx
  
08.01.90aAmivantamab-vmjw(Rybrevant®)08.01.90aPharmacy (08)Amivantamab-vmjw (Rybrevant®)22e3725e-1aab-4c4e-a86b-bd4cb90f60b26324Amivantamab-vmjw (Rybrevant®)08.01.90
142c8236-6430-4f8e-99d8-3cc44fc27dca.aspx
  
01.00.12cAnesthesiaServicesforEpidural,ParavertebralFacetandSacroiliacJointInjectionsforSpinalJointManagement01.00.12cAnesthesia (01)Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management142c8236-6430-4f8e-99d8-3cc44fc27dca6675Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management01.00.12
{"6676": {"Id":6676,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9043,"PolicyAttachmentPageName":"9198205f-cc8f-4dc8-8637-891b21ef044c"},}
d76f0864-8820-4305-aef9-042ca7cef74f.aspx
  
08.01.82cAnifrolumab-fnia(Saphnelo®)08.01.82cPharmacy (08)Anifrolumab-fnia (Saphnelo®)d76f0864-8820-4305-aef9-042ca7cef74f6388Anifrolumab-fnia (Saphnelo®)08.01.82
a37cd522-7951-47b7-bbe2-ef62cfe0fe2f.aspx
  
05.00.39vAnkle-Foot/Knee-Ankle-FootOrthoses05.00.39vDME (05)Ankle-Foot/Knee-Ankle-Foot Orthosesa37cd522-7951-47b7-bbe2-ef62cfe0fe2f7171Ankle-Foot/Knee-Ankle-Foot Orthoses05.00.39
{"7172": {"Id":7172,"MPAttachmentLetter":"A","Title":"HCPCS Codes","MPPolicyAttachmentInternalSourceId":9568,"PolicyAttachmentPageName":"27c011db-7e63-49db-8f93-043e0b7f97a0"},}
f620f6fa-4a59-4450-a990-93e43257a6b1.aspx
  
06.03.04oApheresisTherapy06.03.04oPathology and Laboratory (06)Apheresis Therapyf620f6fa-4a59-4450-a990-93e43257a6b16934Apheresis Therapy06.03.04
d639cac9-8dad-420b-896d-b30fd48ea0e9.aspx
  
05.00.84Apos®biomechanicalshoesystem05.00.84DME (05)Apos® biomechanical shoe systemd639cac9-8dad-420b-896d-b30fd48ea0e96859Apos® biomechanical shoe system05.00.84
585fcd79-7a3a-47af-8791-80a5d1d21317.aspx
  
11.08.05gApplicationandRemovalofTattoos11.08.05gSurgery (11)Application and Removal of Tattoos585fcd79-7a3a-47af-8791-80a5d1d213176047Application and Removal of Tattoos11.08.05
b635799b-2e23-43e5-adc9-0dfcfe2217b9.aspx
  
14.00.03aAppliedBehaviorAnalysis(ABA)fortheTreatmentofAutismSpectrumDisorders(ASD)14.00.03aBehavioral Health (14)Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorders (ASD)b635799b-2e23-43e5-adc9-0dfcfe2217b96596Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorders (ASD)14.00.03
313650d2-3c00-43a3-ad1b-36d6fd45655e.aspx
  
11.05.16lAqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucoma11.05.16lSurgery (11)Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma313650d2-3c00-43a3-ad1b-36d6fd45655e6331Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma11.05.16
{"6332": {"Id":6332,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":8590,"PolicyAttachmentPageName":"e47bb55c-5b65-4d50-8799-56ca8fc7ba90"},}
ca8705e7-f5e4-43fe-aba0-460c9e68fa27.aspx
  
11.14.19pArtificialIntervertebralCervicalDiscInsertion(IndependenceAdministrators)11.14.19pSurgery (11)Artificial Intervertebral Cervical Disc Insertion (Independence Administrators)ca8705e7-f5e4-43fe-aba0-460c9e68fa276634Artificial Intervertebral Cervical Disc Insertion (Independence Administrators)11.14.19
ee9b7ce0-a5ec-4384-96fc-8614abab3c08.aspx
  
08.01.35iAsparaginaseErwiniaChrysanthemi(recombinant)-rywn(Rylaze®)08.01.35iPharmacy (08)Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)ee9b7ce0-a5ec-4384-96fc-8614abab3c087010Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)08.01.35
e81aedc0-6fee-4de8-bfe5-37273039c3b6.aspx
  
06.02.27pAssaysofGeneticExpressioninTumorTissueforBreastCancerPrognosis(IndependenceAdministrators)06.02.27pPathology and Laboratory (06)Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)e81aedc0-6fee-4de8-bfe5-37273039c3b67138Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)06.02.27
b753c112-cb1c-4a31-a437-b39ee728998e.aspx
  
07.10.06jAssistedReproductiveTechnologyforInfertilityandOocyteCryopreservation07.10.06jMedicine (07)Assisted Reproductive Technology for Infertility and Oocyte Cryopreservationb753c112-cb1c-4a31-a437-b39ee728998e6522Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation07.10.06
cb80dba0-789a-48f8-97dd-908fdb3d4424.aspx
  
08.01.69eAtezolizumab(Tecentriq®)andAtezolizumabwithHyaluronidase-tqjs(TecentriqHybrezaTM)08.01.69ePharmacy (08)Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza TM)cb80dba0-789a-48f8-97dd-908fdb3d44247190Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza TM)08.01.69
{"7191": {"Id":7191,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9571,"PolicyAttachmentPageName":"52ea1631-04db-4602-a498-1e464e7f662a"},}
a327d3f7-485f-4db6-8738-01d56e324c2f.aspx
  
08.02.24Atidarsageneautotemcel(Lenmeldy)08.02.24Pharmacy (08)Atidarsagene autotemcel (Lenmeldy)a327d3f7-485f-4db6-8738-01d56e324c2f6935Atidarsagene autotemcel (Lenmeldy)08.02.24
854d35ec-1da5-4c9b-96c7-258cc052d5ff.aspx
  
05.00.82AuricularProstheses05.00.82DME (05)Auricular Prostheses854d35ec-1da5-4c9b-96c7-258cc052d5ff6321Auricular Prostheses05.00.82
3bc5cc35-7f80-4494-84dd-eb645cad0fbc.aspx
  
11.14.06jAutologousChondrocyteImplantation(ACI)andOtherCell-basedTreatmentsofFocalArticularCartilageLesions(IndependenceAdministrators)11.14.06jSurgery (11)Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)3bc5cc35-7f80-4494-84dd-eb645cad0fbc7279Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)11.14.06
dd700951-87d5-4759-bb8e-af57f14e4a33.aspx
  
05.00.29oAutomaticExternalCardioverterDefibrillators(WearableandNonwearable)05.00.29oDME (05)Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)dd700951-87d5-4759-bb8e-af57f14e4a337232Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)05.00.29
{"7233": {"Id":7233,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":9496,"PolicyAttachmentPageName":"2a12e22d-6c14-4428-89cd-6eadd3f170f8"},"7234": {"Id":7234,"MPAttachmentLetter":"A","Title":"ICD-10 Codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":9497,"PolicyAttachmentPageName":"b34b8bf3-f2f0-4ead-b9b4-2e7bea974064"},}
2fbad6ab-e991-4724-b940-8fe96c5d52ad.aspx
  
07.03.23gAutonomicNervousSystemTesting07.03.23gMedicine (07)Autonomic Nervous System Testing2fbad6ab-e991-4724-b940-8fe96c5d52ad6696Autonomic Nervous System Testing07.03.23
3f713f51-a7e4-4470-876d-57b93f779c9d.aspx
  
08.01.64dAvelumab(Bavencio®)08.01.64dPharmacy (08)Avelumab (Bavencio®)3f713f51-a7e4-4470-876d-57b93f779c9d6950Avelumab (Bavencio®)08.01.64
{"6951": {"Id":6951,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9267,"PolicyAttachmentPageName":"e06bd658-f9c9-41e2-8b59-c7306cab3eea"},}
06478bb4-9c20-4f00-abbb-6302983f60f0.aspx
  
11.16.06kBalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitisorRecurrentAcuteRhinosinusitis11.16.06kSurgery (11)Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis06478bb4-9c20-4f00-abbb-6302983f60f07209Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis11.16.06
ceb10a20-5469-4ea9-a37a-ca619446cd4f.aspx
  
11.03.02vBariatricSurgery11.03.02vSurgery (11)Bariatric Surgeryceb10a20-5469-4ea9-a37a-ca619446cd4f7057Bariatric Surgery11.03.02
{"7058": {"Id":7058,"MPAttachmentLetter":"A","Title":"Body Mass Index (BMI) Charts","MPPolicyAttachmentInternalSourceId":6615,"PolicyAttachmentPageName":"4ccedb4c-44db-424d-a304-7804c14280b2"},"7059": {"Id":7059,"MPAttachmentLetter":"B","Title":"Tanner Staging System Criteria for Adolescents","MPPolicyAttachmentInternalSourceId":6616,"PolicyAttachmentPageName":"16d586c6-803c-4e75-8539-5b89973a64c9"},}
e31a657f-48be-4a73-9792-130bfcdf2d6c.aspx
  
08.00.99eBelimumab(Benlysta®)forIntravenousUse08.00.99ePharmacy (08)Belimumab (Benlysta®) for Intravenous Usee31a657f-48be-4a73-9792-130bfcdf2d6c6312Belimumab (Benlysta®) for Intravenous Use08.00.99
e6dbad62-468b-468f-b299-699bc381c4b9.aspx
  
08.02.10bBeremageneGeperpavec(Vyjuvek™)08.02.10bPharmacy (08)Beremagene Geperpavec (Vyjuvek™)e6dbad62-468b-468f-b299-699bc381c4b96516Beremagene Geperpavec (Vyjuvek™)08.02.10
eaeb3ab5-7cc1-47ad-b9ed-89caee51d73b.aspx
  
08.01.89aBetibeglogeneAutotemcel[Beti-Cel(ZYNTEGLO®)]08.01.89aPharmacy (08)Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)]eaeb3ab5-7cc1-47ad-b9ed-89caee51d73b6454Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)]08.01.89
400bb492-f2c0-480e-be9e-f0604f9c8cf6.aspx
  
08.00.66wBevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUse08.00.66wPharmacy (08)Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use400bb492-f2c0-480e-be9e-f0604f9c8cf66952Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use08.00.66
{"6953": {"Id":6953,"MPAttachmentLetter":"A","Title":"ICD 10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":9221,"PolicyAttachmentPageName":"0354602f-0ecd-45a0-94c5-e80d8aef3c70"},}
63b306b5-5ef4-41c4-9f81-66980713c4ae.aspx
  
00.10.39qBillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampus00.10.39qAdministrative (00)Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus63b306b5-5ef4-41c4-9f81-66980713c4ae7061Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus00.10.39
{"7062": {"Id":7062,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus","MPPolicyAttachmentInternalSourceId":9408,"PolicyAttachmentPageName":"d649740c-1747-4e88-994c-0736d063563e"},}
21ae79a9-3406-47c5-bb6d-1fae80367998.aspx
  
00.10.38aBillingRequirementsforMultipleBirthsforProfessionalProviders00.10.38aAdministrative (00)Billing Requirements for Multiple Births for Professional Providers21ae79a9-3406-47c5-bb6d-1fae803679986302Billing Requirements for Multiple Births for Professional Providers00.10.38
{"6303": {"Id":6303,"MPAttachmentLetter":"C","Title":"CODING SCENARIOS FOR REPORTING HIGH-ORDER MULTIPLE (TRIPLETS, QUADRUPLETS, ETC) BIRTHS WHEN ROUTINE OBSTETRIC (GLOBAL MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":8677,"PolicyAttachmentPageName":"eb66d5c6-6236-4d27-97a4-bcdd186ff868"},"6304": {"Id":6304,"MPAttachmentLetter":"A","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ROUTINE OBSTETRIC (GLOBALE MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":8678,"PolicyAttachmentPageName":"d50dbf13-85a1-46a6-ba08-f3aa39e2c495"},"6305": {"Id":6305,"MPAttachmentLetter":"D","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF HIGH-ORDER MULTIPLES WHEN ANTEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":8679,"PolicyAttachmentPageName":"e4baa2eb-649c-4057-b59a-482ec93d4622"},"6306": {"Id":6306,"MPAttachmentLetter":"B","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ANETEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":8680,"PolicyAttachmentPageName":"c6801920-f2e5-42bd-8e26-0f6161437f1b"},}
1e2a3057-e8ea-49ef-92d4-e4ffaed58dca.aspx
  
07.00.01nBiofeedbackTherapy07.00.01nMedicine (07)Biofeedback Therapy1e2a3057-e8ea-49ef-92d4-e4ffaed58dca7106Biofeedback Therapy07.00.01
f9a6a3eb-3e75-4270-bf9f-f6b8aff92631.aspx
  
07.06.03bBioimpedancefortheDetectionofLymphedema07.06.03bMedicine (07)Bioimpedance for the Detection of Lymphedemaf9a6a3eb-3e75-4270-bf9f-f6b8aff926316599Bioimpedance for the Detection of Lymphedema07.06.03
7edcdaa3-01b6-4362-9af3-7bf64042887e.aspx
  
08.01.21gBlinatumomab(Blincyto®)08.01.21gPharmacy (08)Blinatumomab (Blincyto®)7edcdaa3-01b6-4362-9af3-7bf64042887e6850Blinatumomab (Blincyto®)08.01.21
7316bfb1-5739-4d96-bf30-14352be2f4fe.aspx
  
11.01.06iBone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAids11.01.06iSurgery (11)Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids7316bfb1-5739-4d96-bf30-14352be2f4fe6235Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids11.01.06
b8b33479-e906-4711-956a-d8c843e74322.aspx
  
09.00.04oBoneMineralDensity(BMD)Testing09.00.04oRadiology (09)Bone Mineral Density (BMD) Testingb8b33479-e906-4711-956a-d8c843e743226269Bone Mineral Density (BMD) Testing09.00.04
bed8434e-8b79-418e-b18e-118a5e7dccd8.aspx
  
08.00.26acBotulinumToxinAgents08.00.26acPharmacy (08)Botulinum Toxin Agentsbed8434e-8b79-418e-b18e-118a5e7dccd86287Botulinum Toxin Agents08.00.26
{"6288": {"Id":6288,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":8524,"PolicyAttachmentPageName":"6eb6cc97-2ca3-4705-b58b-51510cc7122e"},}
eb9a254e-73d9-4294-8eb7-de2cf6cb2057.aspx
  
09.00.10zBrachytherapyandAcceleratedWholeBreastIrradiationusingThree-DimensionalConformationRadiationTherapy09.00.10zRadiology (09)Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapyeb9a254e-73d9-4294-8eb7-de2cf6cb20576083Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy09.00.10
e6da8955-9faa-4c35-abba-8dd07b2e3392.aspx
  
05.00.76hBreastPumps05.00.76hDME (05)Breast Pumpse6da8955-9faa-4c35-abba-8dd07b2e33926625Breast Pumps05.00.76
e1c8211b-a58b-4aae-b82f-c5212944874b.aspx
  
08.01.13kBrentuximabVedotin(Adcetris®)08.01.13kPharmacy (08)Brentuximab Vedotin (Adcetris®)e1c8211b-a58b-4aae-b82f-c5212944874b6872Brentuximab Vedotin (Adcetris®)08.01.13
{"6873": {"Id":6873,"MPAttachmentLetter":"A","Title":"ICD CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":8995,"PolicyAttachmentPageName":"7ce85bb8-9600-4027-ba31-b1e4502bb940"},}
cea694d5-0c4a-4a47-9848-473275304abd.aspx
  
11.16.09BronchialValves11.16.09Surgery (11)Bronchial Valvescea694d5-0c4a-4a47-9848-473275304abd7122Bronchial Valves11.16.09
ebee83c9-0d6f-4f49-9c7b-ac71d2a03bc8.aspx
  
08.01.49bBurosumab-twza(Crysvita®)08.01.49bPharmacy (08)Burosumab-twza (Crysvita®)ebee83c9-0d6f-4f49-9c7b-ac71d2a03bc86263Burosumab-twza (Crysvita®)08.01.49
6d68299b-c238-4530-a432-2136ee8cfa48.aspx
  
08.01.51cCanakinumab(Ilaris®)08.01.51cPharmacy (08)Canakinumab (Ilaris®)6d68299b-c238-4530-a432-2136ee8cfa486945Canakinumab (Ilaris®)08.01.51
{"6946": {"Id":6946,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":9272,"PolicyAttachmentPageName":"117ae255-5a03-4640-bed7-5aaecf45f228"},}
8af288c7-5ed3-48e7-89a3-f3c180c0e9bd.aspx
  
10.01.01rCardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)Programs10.01.01rRehabilitation Services (10)Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs8af288c7-5ed3-48e7-89a3-f3c180c0e9bd7107Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs10.01.01
{"7108": {"Id":7108,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":9418,"PolicyAttachmentPageName":"7a889d8c-2334-4e54-88cb-a49fbe7581f3"},}
64391f7c-d9f5-47dd-937f-7a246ccc7aaf.aspx
  
00.01.59oCareManagementandCarePlanningServices00.01.59oAdministrative (00)Care Management and Care Planning Services64391f7c-d9f5-47dd-937f-7a246ccc7aaf7045Care Management and Care Planning Services00.01.59
b6fb4da7-10aa-4de1-b765-a97b6d6e8c6f.aspx
  
08.01.05lCarfilzomib(Kyprolis®)08.01.05lPharmacy (08)Carfilzomib (Kyprolis®)b6fb4da7-10aa-4de1-b765-a97b6d6e8c6f6871Carfilzomib (Kyprolis®)08.01.05
713595c4-c9ab-4fea-8792-7e96084b0f34.aspx
  
08.02.14Casgevy™(exagamglogeneautotemcel)08.02.14Pharmacy (08)Casgevy™ (exagamglogene autotemcel)713595c4-c9ab-4fea-8792-7e96084b0f346907Casgevy™ (exagamglogene autotemcel)08.02.14
f52f2efa-c59c-42e0-81cd-e6bf24c6cd3e.aspx
  
00.10.15dCastandSplintApplicationsandAssociatedSupplies00.10.15dAdministrative (00)Cast and Splint Applications and Associated Suppliesf52f2efa-c59c-42e0-81cd-e6bf24c6cd3e6629Cast and Splint Applications and Associated Supplies00.10.15
{"6630": {"Id":6630,"MPAttachmentLetter":"A","Title":"Procedure Codes Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":8996,"PolicyAttachmentPageName":"fd33be68-8e44-4b85-992e-1da428d46692"},}
a2ad5881-a3e9-4937-ae77-77d65bf7d834.aspx
  
11.01.07gCataractSurgery11.01.07gSurgery (11)Cataract Surgerya2ad5881-a3e9-4937-ae77-77d65bf7d8346389Cataract Surgery11.01.07
{"6390": {"Id":6390,"MPAttachmentLetter":"A","Title":"ICD 10 codes for Cataract Surgery","MPPolicyAttachmentInternalSourceId":8501,"PolicyAttachmentPageName":"59ad3d31-e989-4d36-a0e4-6a2913416a22"},}
16476590-a27f-4cbe-ada7-cbae7f72ec66.aspx
  
11.02.06rCatheterAblationofCardiacArrhythmias11.02.06rSurgery (11)Catheter Ablation of Cardiac Arrhythmias16476590-a27f-4cbe-ada7-cbae7f72ec666979Catheter Ablation of Cardiac Arrhythmias11.02.06
6b32b36f-1f58-42d1-b90e-32ddb34e2702.aspx
  
08.01.66dCemiplimab-rwlc(Libtayo®)08.01.66dPharmacy (08)Cemiplimab-rwlc (Libtayo®)6b32b36f-1f58-42d1-b90e-32ddb34e27026876Cemiplimab-rwlc (Libtayo®)08.01.66
a969b8f9-a858-4c56-9705-1e4c094fef97.aspx
  
08.01.39dCerliponasealfa(Brineura®)08.01.39dPharmacy (08)Cerliponase alfa (Brineura®)a969b8f9-a858-4c56-9705-1e4c094fef976894Cerliponase alfa (Brineura®)08.01.39
{"6895": {"Id":6895,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements for Cerliponase alfa (Brineura®)","MPPolicyAttachmentInternalSourceId":9269,"PolicyAttachmentPageName":"447514b5-e4b2-432a-ae7e-6945a44abadb"},}
eef2e9b2-aab5-4cca-ab3c-ed452e909887.aspx
  
05.00.61hCervicalTractionDevicesforIn-homeUse05.00.61hDME (05)Cervical Traction Devices for In-home Useeef2e9b2-aab5-4cca-ab3c-ed452e9098877033Cervical Traction Devices for In-home Use05.00.61
c6349587-f8ed-4988-af17-d7556abd45f7.aspx
  
08.00.67oCetuximab(Erbitux®)08.00.67oPharmacy (08)Cetuximab (Erbitux®)c6349587-f8ed-4988-af17-d7556abd45f76072Cetuximab (Erbitux®)08.00.67
{"6073": {"Id":6073,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":8346,"PolicyAttachmentPageName":"9aabc33b-6deb-4111-b60b-c53feaa2873a"},"6074": {"Id":6074,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":8347,"PolicyAttachmentPageName":"48abba96-d1ea-441e-b9a7-92ebc0eefaa0"},}
fa54024b-27e8-4670-8cab-64dbc90cc3ce.aspx
  
11.08.08hChemicalPeels11.08.08hSurgery (11)Chemical Peelsfa54024b-27e8-4670-8cab-64dbc90cc3ce6742Chemical Peels11.08.08
589bda9a-93e2-4d00-b888-34c929d207dc.aspx
  
08.01.43pChimericAntigenReceptor(CAR)Therapy08.01.43pPharmacy (08)Chimeric Antigen Receptor (CAR) Therapy589bda9a-93e2-4d00-b888-34c929d207dc7113Chimeric Antigen Receptor (CAR) Therapy08.01.43
a6a3818c-0215-4ef6-b633-abb5fd0d5924.aspx
  
10.02.02kChiropracticSpinalandExtraspinalManipulationTherapy10.02.02kRehabilitation Services (10)Chiropractic Spinal and Extraspinal Manipulation Therapya6a3818c-0215-4ef6-b633-abb5fd0d59246440Chiropractic Spinal and Extraspinal Manipulation Therapy10.02.02
22407481-f481-42a9-8ca9-02d6f2ba1672.aspx
  
08.00.92aiCoagulationFactors08.00.92aiPharmacy (08)Coagulation Factors22407481-f481-42a9-8ca9-02d6f2ba16727193Coagulation Factors08.00.92
84c1878f-0009-47d5-8883-e6a2090ddade.aspx
  
06.02.54cCobalamin(VitaminB12),FolicAcid,andHomocysteineTesting06.02.54cPathology and Laboratory (06)Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing84c1878f-0009-47d5-8883-e6a2090ddade6494Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing06.02.54
{"6495": {"Id":6495,"MPAttachmentLetter":"A","Title":"MEDICALLY NECESSARY ICD 10 CODES FOR COBALAMIN (VITAMIN B12) AND/OR FOLIC ACID TESTING (CPT CODES 82607, 82608, 82746, AND 82747)","MPPolicyAttachmentInternalSourceId":8879,"PolicyAttachmentPageName":"9dc800e1-edd4-4398-bbb2-ee5429c669d4"},}
185c05ea-869a-40ce-8dd6-f9b76250041b.aspx
  
11.01.02rCochlearImplantation11.01.02rSurgery (11)Cochlear Implantation185c05ea-869a-40ce-8dd6-f9b76250041b6234Cochlear Implantation11.01.02
6b93ebde-1aec-4421-b9c8-1ccbc2354194.aspx
  
08.01.71Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo®)08.01.71Pharmacy (08)Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®)6b93ebde-1aec-4421-b9c8-1ccbc23541946053Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®)08.01.71
86537148-8562-4da7-87ef-9ebe5abed28b.aspx
  
11.03.12uColorectalCancerScreening11.03.12uSurgery (11)Colorectal Cancer Screening86537148-8562-4da7-87ef-9ebe5abed28b6541Colorectal Cancer Screening11.03.12
bd65e1a4-f2f6-4bee-92f1-e5ace6a688d6.aspx
  
12.00.03hComplementaryandIntegrativeHealthServices12.00.03hMiscellaneous (12)Complementary and Integrative Health Servicesbd65e1a4-f2f6-4bee-92f1-e5ace6a688d66308Complementary and Integrative Health Services12.00.03
380691f8-a783-41d2-9c89-5180c9877c3e.aspx
  
07.06.01bCompleteDecongestiveTherapy(CDT)07.06.01bMedicine (07)Complete Decongestive Therapy (CDT)380691f8-a783-41d2-9c89-5180c9877c3e6538Complete Decongestive Therapy (CDT)07.06.01
2b5ef5e6-615c-4d34-8f9e-8e49c34dcdfb.aspx
  
11.14.30CompositeTissueAllotransplantationoftheHand(s)andFace11.14.30Surgery (11)Composite Tissue Allotransplantation of the Hand(s) and Face2b5ef5e6-615c-4d34-8f9e-8e49c34dcdfb6151Composite Tissue Allotransplantation of the Hand(s) and Face11.14.30
d2119750-381b-413e-a14f-c6b03d6c4d86.aspx
  
05.00.37jCompressionGarments05.00.37jDME (05)Compression Garmentsd2119750-381b-413e-a14f-c6b03d6c4d867265Compression Garments05.00.37
7ddb691f-96da-4a27-8844-7dea1647eacf.aspx
  
09.00.42dComputer-AidedDetection(CAD)SystemforUsewithChestRadiographs09.00.42dRadiology (09)Computer-Aided Detection (CAD) System for Use with Chest Radiographs7ddb691f-96da-4a27-8844-7dea1647eacf6614Computer-Aided Detection (CAD) System for Use with Chest Radiographs09.00.42
34a2f226-750f-40db-a9d0-44decc11aea8.aspx
  
11.14.17eComputer-assistedMusculoskeletalSurgicalNavigationalOrthopedicProcedure11.14.17eSurgery (11)Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure34a2f226-750f-40db-a9d0-44decc11aea86080Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure11.14.17
6b345f32-5fc3-4d8f-b455-be8e91900cb5.aspx
  
00.01.69bConsultationServices00.01.69bAdministrative (00)Consultation Services6b345f32-5fc3-4d8f-b455-be8e91900cb56315Consultation Services00.01.69
afc99979-3413-4a85-b648-62fe9a7ee219.aspx
  
07.13.11kContactLensesfortheTreatmentofPersistent(Corneal)EpithelialDefects07.13.11kMedicine (07)Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defectsafc99979-3413-4a85-b648-62fe9a7ee2196533Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects07.13.11
{"6534": {"Id":6534,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":8891,"PolicyAttachmentPageName":"008ec9e5-6f90-4469-8add-4589230fd5d3"},}
d7def89b-2c58-49c2-b6c4-4281d66bb663.aspx
  
09.00.11eContrastAgentsUsedinConjunctionwithEchocardiography09.00.11eRadiology (09)Contrast Agents Used in Conjunction with Echocardiographyd7def89b-2c58-49c2-b6c4-4281d66bb6637136Contrast Agents Used in Conjunction with Echocardiography09.00.11
ccbf392a-076f-491f-81a7-7c009973654a.aspx
  
07.13.07lCornealPachymetryUsingUltrasound07.13.07lMedicine (07)Corneal Pachymetry Using Ultrasoundccbf392a-076f-491f-81a7-7c009973654a6421Corneal Pachymetry Using Ultrasound07.13.07
{"6422": {"Id":6422,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":8841,"PolicyAttachmentPageName":"3feca23c-4a29-4511-9186-8c5a3d9fe191"},}
16a6341d-dae7-4e4c-9304-35dfd83a1dcd.aspx
  
09.00.58CoronaryArteryCalcium(CAC)TestingUsingComputedTomography(IndependenceAdministrators)09.00.58Radiology (09)Coronary Artery Calcium (CAC) Testing Using Computed Tomography (Independence Administrators)16a6341d-dae7-4e4c-9304-35dfd83a1dcd6205Coronary Artery Calcium (CAC) Testing Using Computed Tomography (Independence Administrators)09.00.58
db363d81-2a6f-410c-93a0-2683359b4855.aspx
  
12.01.03bCosmeticProcedures12.01.03bMiscellaneous (12)Cosmetic Proceduresdb363d81-2a6f-410c-93a0-2683359b48557051Cosmetic Procedures12.01.03
b463e0d4-cc67-4b23-a012-38a027097061.aspx
  
08.01.08tCoverageofAnticancerPrescriptionOralandInjectableDrugsandBiologicsandSupportiveAgents08.01.08tPharmacy (08)Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agentsb463e0d4-cc67-4b23-a012-38a0270970617194Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents08.01.08
{}
aa807c48-d1a3-4b18-bad0-2b8f3e3f8dc0.aspx
  
05.00.04eCoverageofMedicalDevices05.00.04eDME (05)Coverage of Medical Devicesaa807c48-d1a3-4b18-bad0-2b8f3e3f8dc06825Coverage of Medical Devices05.00.04
e09e0da7-d349-4852-8d61-0dbc6ecd6b83.aspx
  
05.00.80dCranialElectrotherapyStimulation05.00.80dDME (05)Cranial Electrotherapy Stimulatione09e0da7-d349-4852-8d61-0dbc6ecd6b836378Cranial Electrotherapy Stimulation05.00.80
3ac82d0c-32e3-4a54-be0e-fc60783c4108.aspx
  
05.00.25jCranialRemoldingOrthoses(Helmets)05.00.25jDME (05)Cranial Remolding Orthoses (Helmets)3ac82d0c-32e3-4a54-be0e-fc60783c41087052Cranial Remolding Orthoses (Helmets)05.00.25
dfd4ab70-1b25-4431-9e64-8919d5b988ea.aspx
  
00.10.03lCriteriaforReimbursementofEmergencyRoomServices00.10.03lAdministrative (00)Criteria for Reimbursement of Emergency Room Servicesdfd4ab70-1b25-4431-9e64-8919d5b988ea6877Criteria for Reimbursement of Emergency Room Services00.10.03
f3947580-94ff-4833-9972-eae6958cb8ca.aspx
  
08.00.04acrizanlizumab-tmca(Adakveo®)08.00.04aPharmacy (08)crizanlizumab-tmca (Adakveo®)f3947580-94ff-4833-9972-eae6958cb8ca6336crizanlizumab-tmca (Adakveo®)08.00.04
d897877c-e6c6-4015-bb59-e60c538c3ec9.aspx
  
08.02.31Crovalimab-akkz(Piasky)08.02.31Pharmacy (08)Crovalimab-akkz (Piasky)d897877c-e6c6-4015-bb59-e60c538c3ec96944Crovalimab-akkz (Piasky)08.02.31
772de3ff-5ca6-4596-9258-6266ee2c4bfc.aspx
  
11.11.03dCryosurgicalAblationoftheProstateGland11.11.03dSurgery (11)Cryosurgical Ablation of the Prostate Gland772de3ff-5ca6-4596-9258-6266ee2c4bfc7249Cryosurgical Ablation of the Prostate Gland11.11.03
370f27b0-7c52-4adb-a6b5-badb05e0aea2.aspx
  
08.01.29lDaratumumab(Darzalex®),DaratumumabandHyaluronidase-fihj(DarzalexFaspro®)08.01.29lPharmacy (08)Daratumumab (Darzalex®), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro®)370f27b0-7c52-4adb-a6b5-badb05e0aea26570Daratumumab (Darzalex®), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro®)08.01.29
428fce04-72cd-4183-803d-dd7bc0f01d5d.aspx
  
10.00.02cDayRehabilitation10.00.02cRehabilitation Services (10)Day Rehabilitation428fce04-72cd-4183-803d-dd7bc0f01d5d6795Day Rehabilitation10.00.02
3a694b1d-646f-4bfd-8ca3-ffd9740e57e0.aspx
  
11.08.17kDebridementofMycoticandSymptomaticNon-MycoticHypertrophicToenails11.08.17kSurgery (11)Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toenails3a694b1d-646f-4bfd-8ca3-ffd9740e57e07224Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toenails11.08.17
{"7225": {"Id":7225,"MPAttachmentLetter":"E","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (S86.892A - Z79.01), Continued","MPPolicyAttachmentInternalSourceId":9486,"PolicyAttachmentPageName":"a1adf17e-24b4-4ec6-94da-201193bfdd17"},"7226": {"Id":7226,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E10.22 - E13.3512), Continued","MPPolicyAttachmentInternalSourceId":9487,"PolicyAttachmentPageName":"be268b19-c2ec-469b-8a05-21e36092f7b5"},"7227": {"Id":7227,"MPAttachmentLetter":"D","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (I87.099 - S86.891S), Continued","MPPolicyAttachmentInternalSourceId":9488,"PolicyAttachmentPageName":"d6f91d4e-1174-459a-a667-714ea4fa1381"},"7228": {"Id":7228,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (A30.0 -E10.21)","MPPolicyAttachmentInternalSourceId":9489,"PolicyAttachmentPageName":"24330fcc-9652-415a-ba12-b7cd20f4aeb0"},"7229": {"Id":7229,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E13.3513 - I87.093), Continued","MPPolicyAttachmentInternalSourceId":9490,"PolicyAttachmentPageName":"40540ab7-a983-4b85-9de3-b2a795f23e98"},}
1 - 100Next
Connect with Us

2025 Independence Blue Cross

Independence Blue Cross is a subsidiary of Independence Health Group, Inc. — independent licensees of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.